Antares Pharma (ATRS) Misses Q3 EPS by 1c

Antares Pharma (NASDAQ: ATRS) reported Q3 EPS of ($0.04), $0.01 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $13.5 million versus the consensus estimate of $11.15 million.

For earnings history and earnings-related data on Antares Pharma (ATRS) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Bernstein SocGen Reiterates Outperform Rating on Fervo Energy (FRVO)
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity